Wire · opportunities
AstraZeneca strikes $40 million AI drug discovery deal with insitro
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
AstraZeneca has entered a $40 million upfront deal with AI biotech insitro to discover new treatments for liver and heart diseases using insitro's AI platform; the collaboration may yield up to $1.46 billion in milestones and royalties. The partnership targets metabolic dysfunction-associated steatohepatitis and cardiomyopathies, focusing on identifying causal disease biology through AI and lab-grown cell models.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 15 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
AI drug discovery is advancing from theory to valuable partnerships for biopharma innovators in liver and heart disease. You can leverage AI to identify disease drivers early and reduce lab testing, speeding up your drug pipeline development.
◆ Coverage
5 sources · first reported 15 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics